ストックスクリーナーアプリを入手
0.1882
0.96%
0.0014
前日終値:
$0.1868
開ける：
$0.188
24時間の取引高:
17.60M
Relative Volume:
0.50
時価総額：
$35.30M
収益：
-
当期純損益:
$-121.02M
株価収益率:
-0.0101
EPS:
-18.6875
ネットキャッシュフロー:
$-114.09M
1週間 パフォーマンス:
-0.11%
1か月 パフォーマンス:
+35.39%
6か月 パフォーマンス:
-96.36%
1年 パフォーマンス:
-98.89%
1日の値動き範囲:
$0.1838
$0.1988
1週間の範囲:
$0.18
$0.2097
52週間の値動き範囲:
$0.118
$22.14
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
名前
Tonix Pharmaceuticals Holding Corp
セクター
電話
212-980-9155
住所
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
0.1883 | 35.30M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.96 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.12 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.93 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.31 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.50 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-04-18 | 開始されました | Noble Capital Markets | Outperform |
| 2019-04-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2017-08-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2016-09-07 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 繰り返されました | Oppenheimer | Outperform |
| 2015-11-04 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-12 | 開始されました | Oppenheimer | Outperform |
| 2015-02-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-29 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Tonix Pharmaceuticals Holding Corp (TNXP) 最新ニュース
Tonix Pharmaceuticals Holding (STU:TPM0) Operating Income : €-74.27 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) EBITDA per Share : €-24.48 (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) FCF Yield % : -195.15 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) EV-to-Revenue : 1.46 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) Capex-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) PS Ratio : 27.04 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Inventories, Inven - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Long-Term Debt : €4.66 Mil (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Retained Earnings : €-638.44 Mil (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Earnings Yield % : N/A% (As of Nov. 30, 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Shares Outstanding (EO - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) 5-Year Yield-on-Cost % : 0.00 (As of Nov. 28, 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Cash Flow from Operati - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Earnings Power Value (EPV) : $-3.87 (As of Sep24) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Free Cash Flow per Sha - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Cash, Cash Equivalents, Marketable Securities : $28.23 Mil (As of Sep. 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Future 3-5Y Total Reve - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Debt-to-Revenue : 0.77 (As of Sep. 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Operating Margin % : -492.06% (As of Sep. 2024) - GuruFocus.com
Tonix Pharma talks NDA for Fibromyalgia drug, FDA decision on NDA acceptance expected December 2024 - Proactive Investors USA
Tonix Pharmaceuticals Holding (FRA:TPM0) Effect of Exchange Rate Changes : €-0.03 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference - The Manila Times
Tonix Pharmaceuticals to Present Pipeline Updates, $34M DoD Contract at NobleCon20 | TNXP Stock News - StockTitan
Monkey Pox Treatment Market Advancements Highlighted by Growth, Size & Forecast 2024-2033 - WhaTech
Tonix Pharmaceuticals Holding (STU:TPM0) Free Cash Flow : €-63.32 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) EV-to-Revenue : 0.99 (As of Nov. 20, 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Enterprise Value : $10.87 Mil (As of Nov. 20, 2024) - GuruFocus.com
Can Tonix Pharma's TNX-102 SL End The 15-Year Drug Drought In Fibromyalgia? - RTTNews
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual - The Manila Times
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - The Manila Times
Tonix's Fibromyalgia Drug Shows Breakthrough Results in Phase 3 Trial, FDA Decision Looming | TNXP Stock News - StockTitan
TNXP (Tonix Pharmaceuticals Holding) Interest Coverage : N/A (As of Jun. 2024) - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in Tonix Pharmaceutica - GuruFocus.com
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments - AccessWire
KEMRI partners with US firm Tonix Pharmaceuticals to develop mpox vaccine - The Eastleigh Voice News
Tonix reports less virulent mpox vaccine candidate - Investing.com India
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - The Manila Times
Tonix Pharma to Present Key Fibromyalgia Drug Data, Awaits FDA Decision on Fast-Tracked Treatment | TNXP Stock News - StockTitan
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals - The Manila Times
Tonix's TNX-801 Vaccine Shows Breakthrough Safety Results, 1000x More Effective Than Legacy Vaccines | TNXP Stock News - StockTitan
Tonix Pharma earnings beat by $2.70, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tonix Pharmaceuticals Files FDA Application for First New Fibromyalgia Drug in 15 Years | TNXP Stock News - StockTitan
Tonix Pharma Unveils Promising TNX-1700 Cancer Data - TipRanks
Tonix presents new data on TNX-801 mpox vaccine - BioWorld Online
Tonix Pharma Partners for Vaccine Clinical Trial - Yahoo Finance
Tonix Pharmaceuticals Holding Corp. Announces Research Agreement with Kenya Medical Research Institute to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - Marketscreener.com
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - The Manila Times
Tonix Pharmaceuticals (TNXP) Earnings Date and Reports 2024 - MarketBeat
Tonix reports promising mpox vaccine candidate data By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals Holding Corp (TNXP) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
0.10%
大文字化:
|
ボリューム (24 時間):